China's Medical Device Exports Shift Focus.
Customs data from China indicates a subtle shift in the export focus of Chinese medical devices. In 2023, exports to the United States market saw a year-on-year decrease of 19.2%, exports to Japan fell by 26.2%, shipments to Germany dropped by 40.8%, and exports to the United Kingdom plummeted by 46.1%.
In the first quarter of 2024, against the backdrop of a significant decline in the previous year, exports of Chinese medical devices to mature markets in Europe, America, and Japan continued to show a trend of slowing growth. Specifically, exports to the Japanese market were $829 million, down 9.56% year-on-year, while exports to the U.S. market were $3.167 billion, with a slight increase of 1.18% year-on-year. It is evident that over the past two years, exports of Chinese medical devices to developed markets in Europe, America, and Japan have significantly declined, with growth rates slowing down.
On the other hand, exports to emerging markets such as the Middle East are experiencing rapid growth. The United Arab Emirates, Turkey, and Saudi Arabia are the three major medical device markets in the Middle East. In the first quarter of 2024, exports to the UAE grew by 23.41% year-on-year; exports to Turkey grew by 9.68%; and exports to Saudi Arabia increased by 8.34%.
Notably, in the first quarter of 2024, in the ranking of the growth rate of China's medical device exports (markets over $100 million), the UAE, Turkey, and Saudi Arabia all made it into the top ten, ranking first, seventh, and eighth, respectively.
The surge in exports to the Middle East signifies that an increasing number of medical device companies have targeted the Middle Eastern market as an important destination for overseas expansion. It also implies that a cohort of medical device companies has successfully established a foothold in the Middle Eastern market. So, which companies are accelerating their expansion into the Middle Eastern market? Which product categories are selling better in the Middle East? What strategies do chinese companies need for their overseas expansion into the Middle East?
Which Products Are Booming in the Middle East?
In the Middle Eastern market, medical imaging is one of the niche areas where chinese companies have successfully mined for gold.
For instance, several medical imaging products from United Imaging have made their way into top hospitals in the Middle East, such as the Al Tahra Imaging Center, one of the four major medical imaging centers in Egypt, and the Dubai American Hospital, a leading high-end private general hospital in the UAE and the Middle East.
Earlier this year, UAE-based medical technology company Prepaire Labs also purchased a high-end PET/CT product from United Imaging: the UEXPLORER Explorer (the world's first panoramic dynamic PET/CT). This has become the first Total-body PET/CT scanner in the Middle East.
In addition, United Imaging has established cooperation with many high-end medical institutions in the Middle East, including the large medical and health group AI Mana in Saudi Arabia, the first specialized medical institution for blood diseases and cancer treatment and diagnosis in Saudi Arabia, NBCC, King Hussein Cancer Center (KHCC), one of the top six cancer centers in the world, the top private hospital American Hospital Dubai in the UAE, and the top oncology center I-ONE Nuclear Medicine and Oncology Center in Saudi Arabia. The cooperation includes system installation, clinical research, and talent training.
Apart from United Imaging, Neusoft Medical has also provided hundreds of large medical devices to the region, covering more than ten countries in the Middle East such as Algeria, Egypt, and the UAE; Mindray Medical's medical imaging products have also successfully broken into high-end hospitals like the NMC Royal Hospital, a high-end private medical group in the UAE, and Hacettepe University Hospital, one of the top three university hospitals in Ankara, Turkey.
Not only that, but chinese medical imaging manufacturers such as ShenTu Medical, XiangSheng Medical, and Shantou Ultrasonic are also increasing their investments in the Middle East market. For example, considering the dietary structure and body characteristics of the local population, ShenTu Medical has launched the ShenTu RAD(S) series dual-column DR products in the Middle East market, with a bed that can support up to 300 kilograms and has innovated and simplified the process for knee joint imaging.
It is foreseeable that as more chinese manufacturers get a grasp of the Middle East market, chinese medical imaging will significantly increase its market share in the region.
Another niche area where chinese companies have made significant inroads in the Middle East market is genetic testing.
In 2019, the United Arab Emirates (UAE) announced the launch of a nationwide genomics project, aiming to use large-scale population genomic data to establish a predictive, preventive, and personalized healthcare system for the people of the UAE. Concurrently, countries in the Middle East such as Saudi Arabia, Turkey, and Israel have also initiated genomic projects to sequence the genomes of their citizens. Additionally, countries like the UAE, Saudi Arabia, and Israel are developing precision diagnostics closely related to genetic testing.
Undoubtedly, the Middle East has nurtured a vast market for genetic testing. Among the first chinese genomics enterprises to venture into the Middle East market was the BGI Group. In 2019, as the UAE's national genomic project was implemented, the Chinese BGI Group participated in the cooperation, implementation, and delivery. Since then, BGI and its affiliated companies have expanded their operations in the Middle East.
For example, BGI Genomics partnered with the subsidiary of the Saudi Al Faisaliah Group, Tibbiyah Holding, to establish an independent clinical laboratory "Genalive" and participated in the construction of the "BGI-ICBA Desert Life Joint Laboratory." They introduced technologies such as non-invasive prenatal genetic testing, single-gene carrier genetic disease testing, newborn disease testing, hereditary tumor gene testing, and infectious disease testing to the Middle East market.
Additionally, BGI Genomics has collaborated with the Middle East's largest College of American Pathologists (CAP) accredited laboratory group, NRL, in non-invasive prenatal genetic testing technology, aiming to provide the Middle East with world-leading genetic testing services. It is reported that NRL owns three laboratories and also manages the laboratories of several large private hospitals and medical institutions in the UAE, such as the Cleveland Clinic Abu Dhabi and the Imperial College Diabetes Center.
In 2024, BGI continues to rapidly develop in the Middle East market. At the beginning of the year, UAE-based medical technology company Prepaire Labs directly purchased BGI's "super sequencing factory" DNBSEQ-T20×2 (referred to as "T20") ultra-high-throughput sequencer; at the same time, BGI and UAE-based medical technology company Dante Labs signed a memorandum of cooperation, planning to establish customer experience centers in the Middle East.
In addition to BGI, Yewgene has also secured large orders in the Middle East market. In 2021, Yewgene signed an innovative cooperation agreement with the Dubai Police General Headquarters in the UAE to jointly develop a rapid mutation Y-chromosome testing kit. After nearly a year of effort, the cooperative kit has been developed and put into production, officially named "Microreader™ 26 RM-Yplex ID system."
BGI Genomics and other companies such as Berry Genomics and GenEditBio have also started to explore the Middle East market. In 2023, Berry Genomics cooperated with the Saudi Arabian company Ajlan & Bros Medical Company to establish a joint venture. Through the joint venture, Berry Genomics will introduce non-invasive prenatal testing (NIPT) and other genetic testing products to Saudi Arabia and the Middle East market. In the future, both parties will also successively initiate projects to establish genetic testing laboratories locally.
GenEditBio signed a memorandum of cooperation with the leading Saudi Arabian genomic sequencing company Anwa BioSciences in 2024. The two sides will cooperate to use CRISPR gene editing technology to treat gene-related diseases, with the first project being sickle cell anemia. In the future, the two sides will also carry out important cooperation in the field of exploring the Middle East market.
With more and more chinese genetic testing companies entering the Middle East market, it is expected that the export volume of chinese genetic testing products and services to the Middle East market will increase significantly.
The In Vitro Diagnostics (IVD) market in the Middle East is another sector where chinese companies have achieved significant breakthroughs, with many Chinese IVD enterprises making substantial progress in 2023.
For instance, in 2023, Abu Dhabi procured a batch of intelligent testing equipment from Yihong Health to enhance the level of medical intelligence. Concurrently, Yihong Health reached a strategic cooperation with the UAE, preparing to establish an overseas company in Abu Dhabi and to engage in in-depth cooperation with the Abu Dhabi Health Department and several partner institutions in the field of medical intelligence.
In the same year, Mindray Medical's IVD business made a breakthrough in the international market, acquiring over 450 new high-end customers, with more than 110 existing high-end customers purchasing the company's other products. Among these, Mindray partnered with a global chain of laboratories in the UAE, becoming its exclusive hematology supplier in Saudi Arabia, Qatar, Bahrain, and Oman.
Dubai's premier healthcare institution, Sheikh Khalifa Medical City General Hospital, along with numerous teaching hospitals in Turkey and other significant public centralized hospitals, have all made substantial purchases of Mindray's in vitro diagnostic (IVD) products in 2023.
Additionally,Sansure Biotech also won several significant projects in the Middle East in 2023, contributing to a rapid increase in local testing capabilities. The company's localized production and services are advancing swiftly. This year,Sansure Biotech further signed a partnership agreement with Saudi company Al-Arab Medical Laboratories. The collaboration aims to engage in long-term, comprehensive cooperation in the areas of infectious diseases, public health prevention and control, and precise diagnosis and management of chronic diseases such as cancer.
YHLO(Shenzhen YHLO Biotech Co., Ltd.) also saw considerable growth in the Middle East in 2023. It is understood that the company's overseas market added more than 684 new installations of chemiluminescence instruments, marking a year-on-year increase of 500%. Revenue growth in regions such as the Middle East stands out.
Looking at the global IVD market, regions like North America and Western Europe remain the main markets but have reached a relatively stable phase. In contrast, emerging markets represented by China, Russia, India, and the Middle East are experiencing rapid growth with significant market opportunities. Currently, chinese IVD companies are still worth exploring the Middle Eastern market.
Apart from medical imaging, gene testing, and IVD, companies in other medical device sectors have also made sporadic inroads into the Middle Eastern market. For instance, a large Turkish pharmaceutical company purchased two fully automatic soft bag large infusion production lines and supporting equipment from SHINAVA. The Saudi TIJAN Group signed a business cooperation agreement with Weigao Group to sell Weigao's flagship products.
The Middle East Market's Three Key Preferences: Digitalization, High-End, and Localization
The Middle East region, stretching from the eastern and southern Mediterranean to the coast of the Persian Gulf, includes most of West Asia except Afghanistan, Egypt in Africa, and the Caucasus region bordering Russia, encompassing approximately 23 countries and regions, over 15 million square kilometers, and a population of 490 million.
What kind of products or services does the Middle East market favor?
In the Middle East, Saudi Arabia, the United Arab Emirates (UAE), and Turkey represent the three largest medical device markets. Currently, these markets are accelerating the push for digital healthcare and telemedicine, enhancing the digitization within the medical field.
Take Saudi Arabia as an example; the healthcare sector is exploring digital medical service solutions to adapt to new challenges in the health sector. The Saudi government previously allocated 167 billion riyals (approximately $44.5 billion) to support the privatization of hospitals, improve medical education, and achieve the digitization of patient medical records. Supportive policies have been issued to promote the construction of E-health platforms, including electronic medical records, imaging data platforms, radiology information systems, laboratory data systems, auxiliary diagnostics, artificial intelligence, remote nursing, and healthcare.
Against this backdrop, medical products with a high level of digitalization are welcomed in the Middle East. For instance, Mindray Medical's medical imaging equipment, paired with "Ruiying Cloud++," has been favored by many high-end hospitals in the region, and "Ruiying Cloud++" has also played a role in countries such as Saudi Arabia.
It is reported that Mindray Medical's "Ruiying Cloud++" combines new technology applications such as artificial intelligence, the Internet of Medical Things, 5G, and cloud computing, offering 5G intelligent ecological access terminals, obstetrics cloud AI quality control solutions, and cloud AI auxiliary teaching solutions. It expands the application boundaries of ultrasound equipment, meeting different users' imaging interconnection application needs.
Among them, the 5G intelligent ecological terminal brings real-time remote imaging experience to users through mobile portability and plug-and-play methods; the obstetrics cloud AI quality control solution uses cloud intelligence to achieve standardized scanning assistance and real-time imaging quality control, improving the efficiency, consistency, and accuracy of prenatal ultrasound screening. "Ruiying Cloud++" also provides innovative training models for local primary care doctors through professional medical imaging remote training programs.
Similarly, at an exhibition,Microtech Medical reached several cooperations with multiple partners in the Middle East, including diabetes detection systems and digital medical solutions.
In addition to digitalization, the Middle East market is also pursuing high-end medical products. It is understood that both Saudi Arabia and the UAE are developed countries with strong consumption power and highly developed medical tourism, thus having very high demands for medical technology and services. At the same time, over the past two years, both Saudi Arabia and the UAE have been accelerating the construction of public health facilities and improving the quality of medical services.
Under this context, high-end medical devices are welcomed in the Saudi and UAE markets. For example, Neusoft Medical, based on local market demand, focuses on selling high-end products in the Middle East, such as the NeuViz Epoch Infinity CT, NeuAngio 30C Hanwu DSA, and NeuWise PET/CT Cangqiong Zhiyan, and other high-end medical imaging equipment.
From the perspective of the procurement side, UAE-based medical technology company Prepaire Labs has successively purchased high-end products from United Imaging Medical, such as the UEXPLORER Explorer, and the ultra-high-throughput sequencer DNBSEQ-T20×2 (referred to as T20) from BGI.
It is reported that the UEXPLORER Explorer is the world's first panoramic dynamic PET/CT, a true Total body PET/CT, and for the first time, it has achieved a full-body scan from head to toe in one bed position. In terms of performance, the UEXPLORER Explorer has increased sensitivity by nearly 40 times, which can shorten the traditional 20-minute examination to 1/40, achieving a full-body imaging in as fast as 30 seconds, and still providing clear imaging after 9.5 half-lives of drug injection, while supporting low-dose imaging with radioactive tracer doses of 1/40-1/50.
The T20 is an ultra-high-throughput sequencer launched by BGI, capable of completing up to 50,000 human whole-genome sequencing cases per year, setting a new record for global gene sequencer throughput; the cost per case is less than $100, achieving lower scale costs. The T20's single run throughput reaches 42Tb (PE100) or 72Tb (PE150), 4.5 to 7 times that of conventional ultra-high-throughput sequencers.
It is worth mentioning that as one of the three major medical device markets in the Middle East, Turkey has different demands from the Saudi and UAE markets, preferring products with price advantages.
Finally, the Middle East market has high requirements for localized services. On December 24, 2023, the localization employment ratio requirements (Saudization rate) for positions in sales, procurement, and project management in Saudi Arabia officially took effect: the localization rate for healthcare professionals is 60%, for medical device engineering and technical professionals is 30%, and for medical device sales and introduction professionals is 40%. In addition, countries such as the UAE, Qatar, Kuwait, Oman, Bahrain, and Egypt have all issued policies to encourage local manufacturing.
Under this context, chinese medical device companies such as Neusoft Medical, New Industry, Sunshine Biotech, Mindray Medical, and United Imaging Medical have all begun to strengthen their localization layout in the Middle East market. Among them, Neusoft Medical has established a service center, logistics center, and spare parts warehouse in Dubai, covering functions such as sales, service, logistics, training, and marketing, with a local employee localization rate of over 90%; New Industry has set up an overseas wholly-owned subsidiary in Saudi Arabia and has strengthened its local operation capabilities by recruiting local employees and applying for product circulation permits.
Digitalization, high-end, and localization—chinese medical device companies that have grasped the market demands of the Middle East region are making a fortune. However, there is no smooth road when going global. Medical device companies entering the Middle East market also face many risks that cannot be ignored, such as special local regulatory requirements, local employment quotas, and high ESG requirements. At the same time, the Middle East market has high requirements for compliance and data security, which companies aiming to enter the Middle East market need to pay attention to.